Tepthera

Cutting edge technology to develop the medicine of tomorrow. Tepthera was launched in 2018 as a spin-off from the Institute of Molecular Health Sciences at the ETH Zurich. Tepthera's fundament is a set of proprietary platform technologies allowing efficient identification of T cell antigens. These disease relevant antigens will provide the basis for developing personalized therapies in various medical fields such as infectious diseases, autoimmunity and foremost in cancer immunotherapy. At Tepthera, we are convinced that effective therapies and medical products tailored for the individual come into reach and will leave behind the one-size-fits-all medications together with their limitations and side effects. Our vision is to bring medicine to a new level of precision. The founding Team (f.l.t.r): Jan Kisielow PhD, Prof. Manfred Kopf and Franz-Josef Obermair PhD